Atria Wealth Solutions Inc. Decreases Stake in Sanofi (NASDAQ:SNY)

Atria Wealth Solutions Inc. cut its stake in shares of Sanofi (NASDAQ:SNY) by 19.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 17,649 shares of the company’s stock after selling 4,298 shares during the period. Atria Wealth Solutions Inc.’s holdings in Sanofi were worth $851,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its holdings in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after purchasing an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors boosted its position in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after buying an additional 751 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after buying an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares during the last quarter. Finally, GFS Advisors LLC increased its holdings in Sanofi by 1,017.9% during the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after acquiring an additional 11,655 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $53.75 on Tuesday. The company has a 50-day simple moving average of $51.10 and a 200-day simple moving average of $52.55. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market cap of $136.41 billion, a PE ratio of 21.59, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Analyst Ratings Changes

SNY has been the topic of several research reports. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.